BA
LGND icon

BKS Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

BKS Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-5,057
Closed -$866K – 215
2018
Q3 		$866K Buy
+5,057
New +$762K 0.32% 79

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

BKS Advisors's LGND Position: Q4 2018 in Review

BKS Advisors sold out of Ligand Pharmaceuticals (LGND) in Q4 2018, closing a stake of 5,057 shares — an estimated $866K sold.

BKS Advisors first reported a position in LGND in Q3 2018 and held it in 1 quarter. The position peaked at $866K in Q3 2018. 362 funds tracked by Wall St. Rank hold LGND as of Q4 2018.

  • BKS Advisors reported no remaining Ligand Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • BKS Advisors sold 5,057 Ligand Pharmaceuticals shares in Q4 2018, an estimated $866K.
  • BKS Advisors first reported a position in Ligand Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • BKS Advisors's Ligand Pharmaceuticals position peaked at $866K in Q3 2018.
  • 362 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2018.

Based on BKS Advisors's 13F filing for Q4 2018, filed 30 Jan 2019.